Tempest Therapeutics Stock Investor Sentiment

TPST Stock  USD 1.10  0.01  0.92%   
Slightly above 61% of all Tempest Therapeutics' private investors are looking to take a long position. The analysis of the overall investor sentiment regarding Tempest Therapeutics suggests that some traders are interested. Tempest Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Tempest Therapeutics' earnings reports, geopolitical events, and overall market trends.
  

Tempest Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Tempest Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over six months ago at investorplace.com         
TPST Stock Earnings Tempest Therapeutics Beats EPS for Q1 2024
sbwire news
over six months ago at seekingalpha.com         
Tempest Therapeutics reports Q1 results
seekingalpha News
over six months ago at news.google.com         
Tempest Therapeutics Trading Up 1.1 percent - MarketBeat
Google News at Macroaxis
over six months ago at www.macroaxis.com         
Acquisition by Whiting Samuel of 100000 shares of Tempest Therapeutics at 4.66 subject to Rule 16b-3
Macroaxis News
over six months ago at finance.yahoo.com         
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635
Yahoo News
over six months ago at globenewswire.com         
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635
Macroaxis News: globenewswire.com
over six months ago at news.google.com         
Tempest Therapeutics Multiple 2024 Catalysts Make This A Must Watch - Seeking Alpha
Google News at Macroaxis
over six months ago at news.google.com         
Tempest Therapeutics Stock Price Down 6.8 percent - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
Bears are Losing Control Over Tempest Therapeutics, Inc. , Heres Why Its a Buy Now - Yahoo Movies UK
Google News at Macroaxis
over six months ago at finance.yahoo.com         
Tempest Reports New Preclinical Data for TPST-1120in RCC at the AACR Annual Meeting
Yahoo News
over six months ago at benzinga.com         
Why Byrna Technologies Shares Are Trading Higher By Around 7 Here Are Other Stocks Moving In Fridays...
benzinga news
over six months ago at finance.yahoo.com         
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Adva...
Yahoo News
over six months ago at investing.com         
Tempest Therapeutics moves TPST-1120 into phase 3 trial
Investing News at Macroaxis
over six months ago at news.google.com         
Is Tempest Therapeutics Inc a Stock to Watch After Gaining 8.52 percent This Week - InvestorsObserve...
Google News at Macroaxis
over six months ago at news.google.com         
Research Analysts Set Expectations for Tempest Therapeutics, Inc.s Q3 2024 Earnings - Defense World
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Tempest Therapeutics that are available to investors today. That information is available publicly through Tempest media outlets and privately through word of mouth or via Tempest internal channels. However, regardless of the origin, that massive amount of Tempest data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Tempest Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Tempest Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Tempest Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Tempest Therapeutics alpha.

Tempest Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635
08/23/2024
2
Acquisition by Dubensky Thomas W. of 102700 shares of Tempest Therapeutics subject to Rule 16b-3
08/28/2024
3
Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference
09/05/2024
4
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635
09/20/2024
5
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial
10/10/2024

Additional Tools for Tempest Stock Analysis

When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.